NCT02259374

Brief Summary

TAP block performed under ultrasound guidance is used as part of multimodal analgesia to relieve pain after abdominal surgery in our hospital. Choices of local anaesthetic used include bupivacaine and ropivacaine. Local anaesthetic works by inhibiting nerve transmission of pain from the site of tissue injury. An important component of the pain experienced by patients after abdominal surgery derives from the abdominal wall incision. The abdominal wall sensory afferents course through the transversus abdominis (neurofascial) plane superficial to the transversus abdominis muscle. Single shot TAP block has been shown to provide pain relief of up to 24h in surgeries involving pfannenstiel incisions, hence a study period of 24h is chosen in patients undergoing hysterectomy. This study was designed to test the hypothesis that the TAP block, as part of a multimodal analgesic regimen, even at a lower concentration, would provide effective analgesia in the first 24 h after hysterectomy, in comparison to a higher concentration of 0.4% ropivacaine.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
54

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Oct 2014

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 30, 2014

Completed
1 day until next milestone

Study Start

First participant enrolled

October 1, 2014

Completed
7 days until next milestone

First Posted

Study publicly available on registry

October 8, 2014

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2015

Completed
Last Updated

October 8, 2014

Status Verified

October 1, 2014

Enrollment Period

1 year

First QC Date

September 30, 2014

Last Update Submit

October 5, 2014

Conditions

Outcome Measures

Primary Outcomes (1)

  • Morphine consumption in the first 24 hours

    24hours

Secondary Outcomes (2)

  • Morphine side effects

    24 hours

  • Patient satisfaction

    24 hours

Study Arms (2)

TAP BLOCK 0.2% ROPIVACAINE

ACTIVE COMPARATOR

Patients randomised into this group will receive bilateral TAP block (single shot) with 0.2% ropivacaine after hysterectomy. Intervention: TAP block Dose: 20 ml 0.2% ropivacaine

Procedure: TAP BLOCK 0.2% ROPIVACAINEProcedure: TAP BLOCK 0.4% ROPIVACAINE

TAP BLOCK 0.4% ROPIVACAINE

ACTIVE COMPARATOR

Patients randomised into this group will receive bilateral TAP block (single shot) with 0.4% ropivacaine after hysterectomy. Intervention: TAP block Dose: 20 ml 0.4% ropivacaine

Procedure: TAP BLOCK 0.2% ROPIVACAINEProcedure: TAP BLOCK 0.4% ROPIVACAINE

Interventions

Patients randomised to this group will receive 20 ml 0.2% Ropivacaine for bilateral TAP block after hysterectomy

TAP BLOCK 0.2% ROPIVACAINETAP BLOCK 0.4% ROPIVACAINE

Patients randomised to this group will receive 20 ml 0.4% Ropivacaine for bilateral TAP block after hysterectomy

TAP BLOCK 0.2% ROPIVACAINETAP BLOCK 0.4% ROPIVACAINE

Eligibility Criteria

Age21 Years - 60 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • \- ASA 1-3
  • age 21-60
  • undergoing open hysterectomy as planned by the surgeons
  • able to provide informed consent. A upper limit age of 60 is chosen because elderly patients may have reduced requirements for analgesia and may be more sensitive to effects of opioids.

You may not qualify if:

  • \- chronic pain/ opioid usage
  • allergy to study drugs
  • BMI\>35
  • Weight \<50

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Interventions

Ropivacaine

Intervention Hierarchy (Ancestors)

AnilidesAmidesOrganic ChemicalsAniline CompoundsAmines

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
ASSOCIATE CONSULTANT

Study Record Dates

First Submitted

September 30, 2014

First Posted

October 8, 2014

Study Start

October 1, 2014

Primary Completion

October 1, 2015

Study Completion

October 1, 2015

Last Updated

October 8, 2014

Record last verified: 2014-10